Certara (CERT) Projected to Post Earnings on Thursday

Certara (NASDAQ:CERT) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $103.2290 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Certara Trading Up 3.1%

Shares of CERT opened at $6.69 on Wednesday. The stock’s fifty day simple moving average is $8.49 and its 200-day simple moving average is $9.96. The firm has a market capitalization of $1.07 billion, a PE ratio of 95.57 and a beta of 1.47. Certara has a 12-month low of $6.32 and a 12-month high of $15.38. The company has a quick ratio of 2.09, a current ratio of 2.09 and a debt-to-equity ratio of 0.27.

Hedge Funds Weigh In On Certara

A number of institutional investors have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. lifted its stake in Certara by 580,097.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company’s stock valued at $7,310,000 after acquiring an additional 829,540 shares during the last quarter. Corient Private Wealth LLC acquired a new stake in Certara in the 4th quarter valued at about $111,000. nVerses Capital LLC bought a new position in Certara during the fourth quarter worth about $184,000. Toronto Dominion Bank grew its holdings in Certara by 186.9% during the fourth quarter. Toronto Dominion Bank now owns 83,939 shares of the company’s stock worth $739,000 after purchasing an additional 54,677 shares during the period. Finally, Oxford Asset Management LLP acquired a new position in Certara during the fourth quarter worth approximately $256,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on CERT shares. BMO Capital Markets began coverage on shares of Certara in a research report on Thursday, November 13th. They set a “market perform” rating and a $9.00 target price on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Rothschild & Co Redburn set a $10.00 target price on shares of Certara in a report on Friday, November 21st. Barclays dropped their target price on shares of Certara from $14.00 to $13.00 and set an “overweight” rating for the company in a research report on Monday, December 15th. Finally, Morgan Stanley reduced their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Certara currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.82.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.